MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Eli Lilly and Company Market Cap 2011-2026 | LLY
As of May 06, 2026 Eli Lilly and Company has a market cap of $ 890 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 940 B | 780 B | 665 B | 297 B | 226 B | 182 B | 137 B | 120 B | 90.6 B | 82.2 B | 87.4 B | 80 B | 59.5 B | 62.1 B | 43.7 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 940 B | 43.7 B | 257 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | France |
 |
Esperion Therapeutics
ESPR
|
561 M | $ 3.13 | 0.39 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
11.7 B | $ 45.86 | 3.23 % | $ 12.5 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Fortress Biotech
FBIO
|
77.8 M | $ 2.51 | 2.03 % | $ 70 M | USA |
 |
Athira Pharma
ATHA
|
1.62 M | - | - | $ 269 M | USA |
 |
Galapagos NV
GLPG
|
4.42 B | $ 28.95 | 1.97 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
25 B | $ 27.7 | 0.59 % | $ 17.1 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
8.42 B | $ 8.37 | 1.2 % | $ 6.83 B |  Spain |
 |
Genprex
GNPX
|
1.65 M | $ 0.9 | 1.28 % | $ 839 K | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 94.84 | -0.69 % | $ 27.2 B | Germany |
 |
InflaRx N.V.
IFRX
|
149 M | $ 2.44 | 24.11 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
348 M | $ 0.81 | 2.15 % | $ 6.7 M |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
12.9 B | $ 76.26 | 1.34 % | $ 12.2 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
52.7 M | - | - | $ 231 M | USA |
 |
Kamada Ltd.
KMDA
|
271 M | $ 8.25 | 0.49 % | $ 260 M |  Israel |
 |
INmune Bio
INMB
|
28.2 M | $ 1.55 | 0.65 % | $ 38.4 M | USA |
 |
Kymera Therapeutics
KYMR
|
7.93 B | $ 85.73 | 3.65 % | $ 7.24 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
132 M | $ 12.98 | -3.49 % | $ 1.72 B | Australia |
 |
ACADIA Pharmaceuticals
ACAD
|
3.19 B | $ 22.93 | 2.6 % | $ 3.8 B | USA |
 |
Liquidia Corporation
LQDA
|
2.95 B | $ 42.33 | 5.48 % | $ 3.64 B | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 3.55 | 1.43 % | $ 5.84 M | Israel |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Mirum Pharmaceuticals
MIRM
|
5.45 B | $ 107.42 | 1.52 % | $ 5.39 B | USA |
 |
MannKind Corporation
MNKD
|
990 M | $ 4.01 | 40.03 % | $ 1.23 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 23.48 | 0.26 % | $ 2.99 B | USA |
 |
Nanobiotix S.A.
NBTX
|
262 B | $ 41.5 | 19.36 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |